Prevalences of human herpesvirus 6 and human herpesvirus 7 in normal Thai population.

Prevalences of human herpesvirus 6 (HHV-6) and human herpesvirus 7 (HHV-7) DNA were investigated in normal Thai population. Peripheral blood mononuclear cells (PBMC) and saliva were collected from 238 healthy adults in five provinces which might be a representative of each part of the country, and 120 normal children in one province. Prevalences of HHV-6 DNA PBMC were 45.5-74.3% in adults and 78.3% in children, and in saliva, very low prevalences were detected; 5.7-8.6% in adults and 15.0% in children, respectively. Additionally, all HHV-6 DNA detected in this study were variant B. Comparingly to those of HHV-7 DNA, the prevalences were significantly higher than those of HHV-6, ie, 82.9-91.4% in PBMC of adults, 85% in PBMC of children, 84.8-89.0% in saliva of adults and 92.5% in saliva of children. HHV-6 and HHV-7 isolation from saliva specimens were also performed. No HHV-6 could be isolated from any samples, whereas, in the present study, HHV-7 could be isolated as 90.0% from children and as 20.0-54.5% from adults.

Seroprevalence of human herpesvirus 6 and 7 infections in the Thai population.

Seroprevalence of human herpesvirus 6 (HHV-6) and 7 (HHV-7) was estimated in the Thai population using indirect immunofluorescence assay to determine serum antibodies to HHV-6 and HHV-7. A total of 333 serum samples obtained from umbilical cord blood and venous blood of healthy persons at Siriraj Hospital and Krabi Hospital during 1990-1993 were investigated. Of 73 infants aged 0-1 month, 73% and 78% were found tob e positive for HHV-6 and HHV-7 antibodies, respectively. Antibody to HHV-6 was detected in age groups 2-3 months (38%), 4-5 months (14%), 6 months (44%), 7-11 months (66%), 1-2 year (84%), 3-4 years (82%), 5-9 years (83%), 10-19 years (83%), 20-29 years (80%), 30-39 years (67%), and over 40 years (58%), respectively. This positive rates of HHV-7 antibody in age groups 2-3 months, 4-5 months, 6 months, 7-11 months, 1-2 years, 3-4 years, 5-9 years, 10-19 years, 21-29 years, 30-39 years, and over 40 years were 50%, 21%, 10%, 37%, 47%, 82%, 75%, 72%, 72%, 67%, and 67%, respectively. At 6 months of age as the starting time of infections, 34% (14/41) and 9% (3/41) of infants had presumed primary infections of HHV-6 and HHV-7, respectively. In the follow-up study, 53% (20/38) of children were infected with HHV-6 prior to HHV-7 and only 5% vice versa. Eighty-four percent of children had acquired antibody to HHV-6 by 1-2 years old while 82% of children had acquired antibody to HHV-7 by 3-4 years old. These results suggest that HHV-6 and HHV-7 are prevalent viruses in the Thai population. The infections of both viruses begin at 6 months of age. However, infection of HHV-7 in most children begins later. The data also provided evidence that antigenic distinction between HHV-6 and HHV-7 existed with a limited cross-reactivity in an antibody test. The antibody responses to HHV-6 and HHV-7 occurred independently.

Effects of human alpha, beta and gamma interferons on varicella zoster virus in vitro.

The antiviral effects of interferon (IFN) on varicella zoster virus (VZV) and herpes simplex virus (HSV) in vitro were examined. The values for the 50% inhibitory dose (ID50) of IFN-alpha, beta and gamma determined by plaque reduction assay, were 0.813, 0.650 and 13.750 IU/ml, respectively, against VZV and 18.00, 10.38 and 115.0 IU/ml, respectively, against HSV. Thus IFN-alpha and beta were more effective than IFN-gamma against both VZV and HSV and VZV was more sensitive than HSV to the IFNs. Five mutants of VZV which were resistant to acyclovir (ACV), phosphonoacetic acid (PAA) or bromodeoxyuridine (BUDR) were also sensitive to IFN beta, their average ID50 being 1.31 IU/ml. Analysis of virus-specific proteins by the immunofluorescent technique with various antisera showed that IFN had a significant effect before early protein synthesis.

Detection of Epstein-Barr virus DNA and HHV-6 DNA in tissue biopsies from patients with nasopharyngeal carcinoma by polymerase chain reaction.

A total of 34 tissue biopsies were collected from nasopharyngeal carcinoma (NPC) patients and 5 controls with non-NPC. Extracted DNA from tissue biopsies were analyzed for presence of specific gene sequences to EBV type A and type B, and HHV-6 by polymerase chain reaction (PCR). The different sequences of EBV type A and B were parts from the highly divergent forms of the EBV nuclear antigen 2 (EBNA 2). The PCR amplified products for EBNA 2A and EBNA 2B were 115 and 119 base pairs respectively whereas that of HHV-6 DNA was 776 base pairs. The results demonstrated that EBV DNA was detected in 32 of 34 cases (94.1%): 28 (82.3%) with type A, 2 (5.9%) with type B, and 2 (5.9%) with both types. EBV DNA of type A could be detected 1 (20%) of 5 controls. HHV-6 DNA was in 5 of 34 samples (14.7%) whereas HHV-6 DNA was not detectable in biopsy tissues from controls. The results show that in the NPC patient group, A type of EBV is predominant. Detection of HHV-6 DNA in patients group only might be resulted from reactivation of a latent infection or association with EBV-induction of NPC.

Immunofluorescence, enzyme-linked immunosorbent assay, particle agglutination and western blot for the detection of antibody to human immunodeficiency virus type 1.

Immunofluorescence assay (IFA) has been applied for detection of antibody to human immunodeficiency virus type 1 (HIV-1). To compare the IFA with an enzyme-linked immunosorbent assay (ELISA) and particle agglutination (PA), we examined the antibody response to HIV-1 in 475 sera from AIDS, PGL and ARC patients as well as several risk groups and healthy persons by three methods. The positive results by any methods were confirmed by western blot (WB). The results by all methods were well correlated on the sera from 45 asymptomatic male homosexuals and 70 female prostitutes. There were some false positive results by ELISA in the sera from prisoners and healthy persons. Four sera from drug abusers were positive only by PA and IFA and were negative by ELISA. All were WB-inconclusive. Particle agglutination and IFA results were compared with western blot analysis on 208 ELISA-positive sera. All IFA-strongly positive sera (84%) were positive by western blot. The sera with weakly positive, negative and inconclusive results by IFA (16%) were possibly any of positive, inconclusive or negative by western blot. By PA, 200 of 208 (97%) sera were PA-positive and 1% of these sera were WB-inconclusive while the PA-negative sera were either negative or inconclusive by western blot. These results suggested that PA is a simple and sensitive method for screening of HIV-1 antibody while IFA could be a primary confirmatory test and western blot would then be used for confirming any IFA-negative or inconclusive results.